Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype

Abstract

Although guidelines are available for hereditary hemochromatosis, a high percentage of the recommendations within them are not shared between the different guidelines. Our main aim is to provide an objective, simple, brief, and practical set of recommendations about therapeutic aspects of HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype, based on the published scientific studies and guidelines, in a form that is reasonably comprehensible to patients and people without medical training. This final version was approved at the Hemochromatosis International meeting on 12th May 2017 in Los Angeles.

Introduction

Although guidelines are available for hereditary hemochromatosis (HH), a high percentage of the recommendations within them are not shared between the different guidelines [1]. Our main aim is to provide an objective, simple, brief, and practical set of recommendations about therapeutic aspects of HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype, based on the published scientific studies and guidelines, in a form that is reasonably comprehensible to patients and people without medical training.

The final version of these recommendations was approved at the Hemochromatosis International meeting on 12th May 2017 in Los Angeles.

Whom to treat and when to start

Patients with HFE p.Cys282Tyr (C282Y/C282Y) homozygous genotype and biochemical evidence of iron overload, i.e., increased serum ferritin (> 300 µg/L in male and postmenopausal female and > 200 µg/L in premenopausal female) and increased fasting transferrin saturation (≥ 45%) [2, 3].

Considerations

  • A judgement has to be made for each individual patient taking into account their ferritin level (according to local reference value), age, gender, and co-morbidities.

  • Patients with other genotypes should be referred for further advice.

  • Recent studies observed a beneficial effect of early and sustained management of patients with iron excess, even when iron load is mild or moderately elevated serum ferritin [4, 5].

  • Elevated serum ferritin values are very common and the most frequent causes are not associated with HH, but with metabolic syndrome inflammation (ferritin is an acute-phase protein), alcoholism, and liver damage. Thus, it is critical to investigate rigorously the cause of high serum ferritin values. Searching for increased plasma transferrin saturation is critical for the diagnosis of HH, since it corresponds to the basic and earliest biochemical abnormality in this disease.

  • Magnetic resonance imaging (MRI), when available, may be used to quantify iron overload in the liver (or in other organs).

Treatment

Phlebotomy (venesection therapy) is the standard treatment for patients with HH having been used for more than 60 years. It is effective in reducing morbidity and mortality of HH [6].

Iron overload leads to tissue injury mainly through the production of reactive oxygen species which damage cell membranes and organelles, ending up with cellular death. Thus, to start the treatment is important.

Each 500 mL phlebotomy withdraws approximately 250 mg of iron which is subsequently released, in a compensatory process, from overloaded tissues (especially the liver), ending up, with phlebotomy repetition, to the total removal of body iron excess.

How to treat

Initial or induction phase

A phlebotomy schedule of the order of 400–500 mL, considering body weight, weekly or every 2 weeks has been proposed [2, 7].

The objective in this phase is usually to reach serum ferritin at 50 µg/L provided that there is no anemia.

Serum ferritin should be checked once a month until the values reach the upper normal limits, and every 2 weeks thereafter, until the final goal of serum ferritin is reached [2, 3, 5].

Considerations

  • The volume and frequency of the phlebotomies should be adapted to the clinical characteristics and (individual) tolerance of the patient.

  • Tolerance: clinical data (general tolerance and blood pressure); hemoglobin (levels should not decrease below 11 g/dL) [7].

  • Phlebotomies can be performed in a clinic, hospital, transfusion/blood donor centers or in certain circumstances at home (by a nurse under medical supervision).

  • Patients should be well hydrated and fed.

Maintenance phase

The maintenance phase follows the induction phase.

The patient with HH needs lifelong follow-up.

One phlebotomy every 1–4 months, depending on the patient’s iron status [2, 7].

Efficacy: the usual aim is to maintain ferritin levels around 50 µg/L (without anemia) [2, 3, 5].

Considerations

  • The frequency of maintenance phlebotomy varies among individuals, ranging from one per month to one per year [3].

  • Hemoglobin levels should not be < 11 g/dL.

  • Hemoglobin value, typically, should be assessed preceding phlebotomy, especially in older patients, who are more susceptible to anemia and chronic blood losses.

  • Serum ferritin should be checked at every other phlebotomy (at the same time as hemoglobin), at least yearly.

  • Fasting transferrin saturation should also be checked, at least once a year.

  • In certain countries, a growing number of patients with uncomplicated hemochromatosis donate blood or qualify as blood donors. Blood removed from therapeutic phlebotomy may be used at the discretion of the blood service [8].

When to stop

Patients who have had iron overload should never stop having their iron status monitored and their treatment planned in the light of their iron status, general condition, and age.

Additional considerations

Diet

A healthy varied diet should be eaten, avoiding foods with iron fortification such as breakfast cereals. Iron and vitamin C supplementation and high alcohol consumption should also be avoided [3]. In certain geographical regions (especially subtropical), HH patients should avoid raw shellfish and undercooked pork because of the risk of severe infections.

Dietary restriction should not replace phlebotomy therapy.

Chelation therapy

Iron chelation is usually indicated for iron overload related to chronic anemias that need repeated transfusions. However, iron chelators are an alternative treatment (or adjuvant) only used in rare and special cases of HH, when phlebotomies are medically contraindicated, simply impossible owing to poor vein conditions, or the efficacy was not achieved with phlebotomies.

Possible future of HH therapeutics

Hepcidin-based therapies might, in future, become a potential adjunct treatment to phlebotomy in the induction phase or a replacement for the phlebotomy maintenance phase. The possibility of using hepcidin is based on the diminishing of hepcidin levels in HH patients, which is responsible for increased serum iron and transferrin saturation, and subsequently to tissue iron overload [9].

References

  1. 1.

    Vanclooster A, et al. The quality of hereditary haemochromatosis guidelines: a comparative analysis. Clin Res Hepatol Gastroenterol 2015;39(2):205–214.

    Article  PubMed  Google Scholar 

  2. 2.

    European Association For The Study Of The Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010;53(1):3–22.

    Article  Google Scholar 

  3. 3.

    Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54(1):328–343.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Bardou-Jacquet E, et al. Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis. J Hepatol 2015;62(3):682–689.

    Article  PubMed  Google Scholar 

  5. 5.

    Ong SY, et al. Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial. Lancet Haematol 2017;4(12):607–614.

    Article  Google Scholar 

  6. 6.

    Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313(20):1256–1262.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Brissot P. Optimizing the diagnosis and the treatment of iron overload diseases. Expert Rev Gastroenterol Hepatol 2016;10(3):359–370.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    De Buck E, Pauwels NS, Dieltjens T, Compernolle V, Vandekerckhove P. Is blood of uncomplicated hemochromatosis patients safe and effective for blood transfusion? A systematic review. J Hepatol 2012;57(5):1126–1134.

    Article  PubMed  Google Scholar 

  9. 9.

    Liu J, Sun B, Yin H, Liu S. Hepcidin: a promising therapeutic target for iron disorders: a systematic review. Medicine (Baltimore) 2016;95(14):e3150.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank for the assistance of the HI members, International BioIron Society, and all consulted experts. Prof. Paulo Santos and Prof. Pierre Brissot were the Chairs during the development of these recommendations.

Author information

Affiliations

Authors

Consortia

Corresponding authors

Correspondence to Pierre Brissot or Paulo Santos.

Ethics declarations

Conflicts of interest

MS, PA, AP, AA, AV, BB, BM, BP, DW, DP, ET, GM, GP, KT, NM, PE, PS, RE, RC, RH, JR, and SD declare no competing financial interests. PB received fees for consulting for La Jolla and Novartis. DS received fees for consulting for “Silence therapeutics” that develop a hepcidin agonist for clinical use. DG has served as consultant (Advisory Board) for La Jolla Pharmaceutical and Silence Therapeutics, regarding possible application of hepcidin agonists for treatment of iron disorders, and also as speaker for Vifor Fresenius Medical Pharma. IC is a consultant for Hinoman Ltd on issues related to iron nutrition in green duckweed and for Aferrix, LtD on methods of detection of potentially toxic forms of iron in plasma/serum of other fluids of humans or animals. EN is a consultant La Jolla Pharmaceutical Company and Protagonist, and a scientific founder and shareholder of Intrinsic LifeSciences, companies involved in the development of diagnostics and therapies for hereditary hemochromatosis. TG is a consultant La Jolla Pharmaceutical Company, and a scientific founder and shareholder of Intrinsic LifeSciences, companies involved in the development of diagnostics and therapies for hereditary hemochromatosis.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Adams, P., Altes, A., Brissot, P. et al. Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype. Hepatol Int 12, 83–86 (2018). https://doi.org/10.1007/s12072-018-9855-0

Download citation